Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Payal Arora

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Clinical Pharmacology and Therapeutics|June 7, 2024
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC)Mineo Matsumoto, Joseph Ryan Polli, Suresh K Swaminathan, et al.
Regulatory Toxicology and Pharmacology : RTP|February 1, 2026
FIH Dose Selection Beyond MABEL: Optimizing Phase 1 clinical trial Starting Dose Whilst Protecting Patient SafetyMineo Matsumoto, J Ryan Polli, Suresh Swaminathan, et al.
Nature Communications|March 21, 2023
Evolutionary conservation of the fidelity of transcriptionClaire Chung, Bert M Verheijen, Zoe Navapanich, et al.
Artificial Intelligence in Medicine|October 2, 2023
Fair and equitable AI in biomedical research and healthcare: Social science perspectivesRenate Baumgartner, Payal Arora, Corinna Bath, et al.
HGG Advances|March 5, 2021
Germline mutation in <i>POLR2A</i>: a heterogeneous, multi-systemic developmental disorder characterized by transcriptional dysregulationAdam W Hansen, Payal Arora, Michael M Khayat, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Clinical Pharmacology and Therapeutics|June 7, 2024
Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno-Safety Technical Committee (ITC)Mineo Matsumoto, Joseph Ryan Polli, Suresh K Swaminathan, et al.
Regulatory Toxicology and Pharmacology : RTP|February 1, 2026
FIH Dose Selection Beyond MABEL: Optimizing Phase 1 clinical trial Starting Dose Whilst Protecting Patient SafetyMineo Matsumoto, J Ryan Polli, Suresh Swaminathan, et al.
Nature Communications|March 21, 2023
Evolutionary conservation of the fidelity of transcriptionClaire Chung, Bert M Verheijen, Zoe Navapanich, et al.
Artificial Intelligence in Medicine|October 2, 2023
Fair and equitable AI in biomedical research and healthcare: Social science perspectivesRenate Baumgartner, Payal Arora, Corinna Bath, et al.
HGG Advances|March 5, 2021
Germline mutation in <i>POLR2A</i>: a heterogeneous, multi-systemic developmental disorder characterized by transcriptional dysregulationAdam W Hansen, Payal Arora, Michael M Khayat, et al.
Pageof 4